INS and type 2 diabetes mellitus: Hence, in this study, we aimed to evaluate changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. in clinical practice in Spain and to analyze different subgroups of patients treated with semaglutide as an add-on to glucose-lowering therapy, semaglutide added, respectively, to noninsulin monotherapy, double/triple noninsulin therapy, basal insulin therapy, and basal-bolus insulin therapy.